Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Headquarters United States of America

Address ., 280 East Grand Avenue, South San Francisco, California, 94080


Telephone 1 650 6243000

No of Employees 253

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange CYTK (NASD)

Revenue (2021) $70.4M 26.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -69.2% (2021 vs 2020)

Market Cap* $3.7B

Net Profit Margin (2021) XXX -34.1% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

50+

Clinical Trials

Determine Cytokinetics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Cytokinetics Inc’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate Cytokinetics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Cytokinetics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

13+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
Omecamtiv Mecarbil: Heart Failure
Reldesemtiv: Spinal Muscular Atrophy and Chronic Obstructive Pulmonary Disease
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In May, the company and The ALS Association announced the continuation of their partnership in the fight against ALS.
2022 Regulatory Approval In February, the company secured FDA approval for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction.
2022 Contracts/Agreements In February, the company and the American Heart Association (AHA) Bay Area entered into a collaboration to accelerate education and awareness of heart disease.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Cytokinetics Inc Regeneron Pharmaceuticals Inc Alexion Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp PTC Therapeutics Inc
Headquarters United States of America United States of America United States of America Japan United States of America
City South San Francisco Tarrytown Boston Osaka South Plainfield
State/Province California New York Massachusetts Osaka New Jersey
No. of Employees 253 10,368 3,837 6,728 1,252
Entity Type Public Public Private Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
John T. Henderson, M.D. Chairman Executive Board 2022 77
Robert I. Blum President; Director; Chief Executive Officer Executive Board 2007 58
Ching W. Jaw Senior Vice President; Chief Financial Officer Senior Management 2017 59
Robert C. Wong Vice President; Chief Accounting Officer Senior Management 2019 55
Kari K. Loeser Chief Compliance Officer; Vice President Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer